<p>The data in this repository is generated from the work of the GBM TeamLab as part of Break Through Cancer (BTC) (<a href="https://breakthroughcancer.org/">https://breakthroughcancer.org/</a>). The TeamLab's goal is to evaluate the feasibility, safety, and value of performing serial brain biopsies to obtain biological readouts during the assessment of novel glibolastoma (GBM) therapeutics. The first investigational agent studied by the TeamLab is a novel oncolytic viral immunotherapy (agent: CAN-3110, also known as rQNestin34.5v.2) which was delivered via repeated intratumoral delivery at up to 6 timepoints over a 4-month period in recurrent IDH-wild type GBM patients. Biopsy tissues, blood, and CSF were collected and subjected to multi-omic profiling at each surgical timepoint. This work is being conducted as one of the trial arms for <a href="https://clinicaltrials.gov/study/NCT03152318">NCT03152318</a>. Controlled access omic data from this study will be deposited here as the results are published.</p>

BTC GBM TeamLab Trial 1: Longitudinal Tissue Profiling of Recurrent    Malignant Glioma During Repeat Dosing of Oncolytic Viral Immunotherapy    (NCT03152318)

Glioblastoma study with AMPLICON, RNA-Seq data on dbGaP (2 participants)

phs004189 — BTC GBM TeamLab Trial 1: Longitudinal Tissue Profiling of Recurrent    Malignant Glioma During Repeat Dosing of Oncolytic Viral Immunotherapy    (NCT03152318)

BTC GBM TeamLab Trial 1: Longitudinal Tissue Profiling of Recurrent Malignant Glioma During Repeat Dosing of Oncolytic Viral Immunotherapy (NCT03152318)

Description

Applying For Access

Summary